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Background: Male infertility of genetic origin affects nearly 1 in 40 men.  Yet 80% of men with 
low sperm production are considered idiopathic due to negative genetic testing.  Based on mouse 
studies there are several hundred possible candidate genes for causing isolated idiopathic male 
infertility due to their involvement in spermatogenesis and male germline-specific expression.  
Although little is known about their pathophysiology and epidemiology in human males, these 
genes represent vast potential for diagnosing and treating infertility.  Lentiviral vector gene 
therapy has recently been shown to be effective in restoring gene expression, and has the 
potential to serve as treatment in male infertility caused by gene defects. 
Methods: This project proposed to use a lentiviral vector to restore spermatogenesis in infertile, 
but viable male mice with a single-gene defect in Sertoli cells as a proof of concept project.  
Candidate genes were identified utilizing the Mouse Genome Informatics (MGI) database and 
literature review.  One of these candidate genes, Dnaja1, was selected for experimental lentiviral 
vector gene therapy in mice.   
Results: Several candidate genes expressed primarily in Sertoli cells known to cause isolated 
azoospermia were identified.  Viral vector preparation was successful, but Dana1-/- mice were 
not produced, possibly indicating embryonic lethality.  
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Conclusion: Because the development of the vector was successful, and with the list of 
candidate genes identified, future experimentation using lentiviral gene therapy to restore 
spermatogenesis caused by single-gene defects is now ready to be performed.  Selecting genes 
expressed in somatic cells, rather than germ cells, maintains the possibility of translating this 
research into clinical treatment for infertility by avoiding ethical implications of genetically 
altering the germ line.  In the future, we hope to perform similar therapy on genes identified 
through the study of men with unexplained infertility.  Of significance to public health, if 
successful this work may represent a novel treatment option for men who are born with single 
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1.0  INTRODUCTION 
Infertility is defined as the failure to conceive after twelve months of unprotected intercourse.  It 
is a health burden with many psychological, economical, and social sequelae that can 
significantly decrease quality of life, and that is often associated with serious medical disorders.  
Male infertility of genetic origin affects nearly 1 in 40 adult men, yet little is known about the 
genetics of isolated infertility, and up to 80% of men with azoospermia or oligozoospermia 
(absent or low sperm production) are considered idiopathic due to negative genetic testing1; 2.  
There is also no direct treatment to restore sperm production in men with idiopathic infertility.  
Treatment options are limited to highly expensive in vitro fertilization which is rarely covered by 
insurance providers, and is ineffective in cases of severe azoospermia or complete absence of 
spermatogenesis3.    
There are several experimental gene therapies that have shown promise in treating 
genetic disorders, including male infertility.  One of these, which has been demonstrated to be 
effective in treating male infertility as well as a number of other genetic diseases is lentiviral 
vector gene therapy4.  Researchers were able to restore spermatogenesis in male mice with a 
gene mutation in the steel factor gene by transfecting the Sertoli cells with a working copy of the 
gene using a lentiviral vector.  However, there is no equivalent to the steel factor gene in human 
males, and mice knockouts were unable to reproduce naturally5. 
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This project aimed to identify candidate genes for experimental gene therapy in male 
mice with isolated infertility, develop a viral vector that can be used to express in Sertoli cells a 
functioning copy of a knocked out gene, and to use this vector to restore spermatogenesis in mice 
with azoospermia.  I identified several candidate genes for experimentation, and we selected a 
gene known to cause isolated azoospermia in mice, Dnaja1, to test the utility of the lentiviral 
therapy6.  We are now prepared to perform similar trials using genes identified in infertile men 
through whole exome sequencing, RNA expression, and array comparative genomic 
hybridization studies.   
1.1 BACKGROUND AND SIGNIFICANCE 
1.1.1 Male Infertility 
Infertility is defined as the failure to conceive after twelve months of unprotected intercourse.  It 
is a health burden with many psychological, economical, and social sequelae that can 
significantly decrease quality of life, and that is often associated with serious medical disorders 
(in about 1 –10% of cases).  Infertility affects ten to fifteen percent of American couples, of 
which half is due to a male factor, meaning the couple’s inability to reproduce is caused by a 
health condition or defect in the male partner7; 8.  Among infertile men, twenty percent have 
azoospermia or oligozoospermia (AZ/OZ), with nearly a third of that due to genetic defects.  
Thus up to one in forty adult men may be affected by genetic infertility1. The cost of diagnosing 
and treating infertility and its complications has been estimated to exceed roughly five billion 
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dollars per year 9; 10. These expenses that are most often placed directly on patients themselves 
due to lack of insurance coverage of infertility diagnosis and treatment in most states 11. 
 
Genetics of Male Infertility 
 
Reproductive success requires thousands of necessary gene products.  The foundation of 
reproduction begins years before the interaction of the sperm and the oocycte, and depends on 
careful coordination and development of multiple systems, including the germline lineage, 
formation of future gonads, genital tracts, etc. 12.   
Up to 50% of male infertility may be of genetic origin.  These include chromosome 
aneuploidies and translocations, Y chromosome microdeletions, X chromosome abnormalities, 
single gene mutations, and DNA mismatch repair and chromosomal recombination defects.  The 
most common chromosome aneuploidies and translocations are Klinefelter syndrome (XXY), 
when a male has two X and one Y chromosome, as opposed to the normal amount of one X and 
one Y.  These also include XYY syndrome, XX male syndrome, mixed gonadal dysgenesis, and 
Robertsonian translocations.  Known Y chromosome microdeletions are located on the AZF 
region, also known as the azoospermic factor region.  These microdeletions account for nearly 
10% of azoospermia and oligozoospermia.  The X chromosome also contains genes important 
for male reproduction. Alterations such as translocations, deletions, and inversions on the X 
chromosome can result in infertility and azoospermia 13.  Knowledge of X Chromosome 
abnormalities causing male infertility, however, is limited to mouse models.  Human subject 
research in this area is needed, but it is postulated that these problems could also be seen in 
human males.   
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There are several single gene mutations known to cause male infertility.  These include, 
but are not limited to, Kallmann syndrome (X-linked and familial), Cystic Fibrosis and CFTR 
mutations, generalized Wolffian duct anomalies, persistent müllerian duct syndrome, insulin – 
like growth receptor mutations, androgen receptor gene mutations, Xq11-11.2, and SRY 
mutations.  Single gene mutations such as these typically occur in less than 1: 20,000 live 
deliveries.  However, mutations in the CFTR gene cause the most common autosomal recessive 
disease in Caucasians, cystic fibrosis, with an incidence of 1 in 2,500 live births.  Non-
obstructive azoospermia involves very low or absent sperm in the ejaculate without any 
structural defects present.  CFTR mutations also account for a large portion of men with non – 
obstructive azoospermia, which represents about 50% of azoospermic men 14 12.    
Much research is required in the area of male infertility, but genomic medicine may one 
day explain a significant portion of idiopathic male infertility.  The majority of research on the 
genetics of male infertility have focused on AZ/OZ 15.  The two types of azoospermia are 
obstructive and nonobstructive.  Obstructive azoospermia is caused by a post – testicular defect 
that results in the failure of sperm to be transported from the testicles to the ejaculate.  This 
condition affects between 7 to 51 percent of men with azoospermia 14, and up to 50% of men 
with obstructive azoospermia carry a Cystic Fibrosis mutation15.  Among men with 
nonobstructive azoospermia, meaning no sperm is being produced by the testes, 10% have Y 
chromosome micro deletions in one of three regions: AZFa, AZFb, and AZFc, and about 4 % 
have Klinefelter syndrome (47, XXY) or other numeric chromosome abnormalities.  Overall, 
about 80% of men with azoospermia or oligozoospermia are considered idiopathic due to 
negative genetic testing. 
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Some work has been done to identify additional candidate genes via animal model 
approaches, but there have been several limitations to identifying novel genes associated with 
male infertility.  These limitations include inappropriate controls, single gene analysis, lack of 
family pedigrees to corroborate significance of findings, and lack of functional studies.  Over 
1,500 genes may be involved in spermatogenesis.  Several hundred of these are expressed 
exclusively in male germ cells, which indicates that they could be candidates for causing isolated 
infertility1.  However, no additional genetic causes are recognized to be important for patient 
care, mainly because results have either not been replicated, explain small effects, or have only 
been seen in mouse models16.  There are over 150 single gene mutations that have been found to 
result in male infertility in mice, most of which affect specific cell types and stages of 
spermatogenesis, including germ cells as well as Somatic cells.  These single gene defects 
represent vast potential for targeted therapy if they are observed in men with infertility17. 
1.1.2 Male Infertility Treatment 
Treatment options available to achieve conception for men with little or absent sperm is very 
limited.  For those with azoospermia or oligozoospermia due to environmental exposures, such 
as gonadotoxin exposure, reduction of these exposures may be useful for reversing damage.  For 
those with endocrine disorders, hormone therapy may allow the revival of sperm production.  In 
cases of incorrect coital timing, counseling the patient is necessary to correct these issues.  
However, for all others, men with idiopathic infertility, there is no direct treatment available to 
restore or increase spermatogenesis.  Conception is only made possible for these men by therapy 
involving in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI) coupled with 
testicular sperm extraction (TESE).  Although this therapy has made it possible for millions of 
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previously infertile men to reproduce, there are several limitations.  For men with severe 
azoospermia, or complete absence of sperm in the testes, also known as Sertoli – cell only 
syndrome, these methods will not be useful for successful reproduction.  IVF, which now 
accounts for nearly 1% of all U.S. births, is also associated with increased birth defect rates 
including hypospadias, cleft lip and palate, septal heart defects, esophageal atresia, Beckwith – 
Weidemann syndrome, and others.  Furthermore, with prices reaching 12,000 – 15,000 dollars, 
IVF is very costly, and rarely covered by insurance3; 18.  The shortcomings of available treatment 
for azoospermia and oligozoospermia highlight the need for a better understanding of the 
genetics of male infertility, as well as the importance of alternative, more direct treatments.  
Understanding the genetic pathology underlying male infertility is imperative for appropriate 
genetic counseling, understanding higher birth defect rates in infertile couples, as well as 
developing safe, alternative, and effective primary treatment of reduced or absent 
spermatogenesis7.   
1.1.3 Experimental Treatment for Male Infertility 
There are several potential prospective treatments with promise for restoring spermatogenesis in 
men with low or absent sperm production; some of which are now in pre-clinical, or clinical trial 
phases, while others remain limited to in vitro and/or animal models.  These include stem cell, 
micro RNA, electroporation, artificial chromosome, circular auto replicating DNA episodes, and 
viral vector therapies.  First, stem cell therapy involves the development of sperm by 
differentiation from pluripotent cells.  Medrano and colleagues at Stanford University recently 
reviewed the current state of research regarding germ cell differentiation from stem cells19.  In 
their research they use induced pluripotent stem cell (iPSC) lines from dermal fibroblasts of 
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infertile men with Sertoli cell only azoospermia.  These stem cells are implanted into the testes 
of mice where they have been used to produce precursors to sperm.  However, there are currently 
several considerable challenges to translating this type of therapy to clinical trials.  Notably, 
achieving fully functional in vitro-derived germ cells has been impeded by issues with epigenetic 
reprogramming of germ cells in vivo, and large differences between species.  These authors 
conclude that future translational applications of stem cell therapy requires an enormous amount 
of work.  Nonetheless, they envision success provided that proper efforts are undertaken19.   
Another experimental form of gene therapy that has been investigated is the use of Micro 
RNA’s.  MiRNAs are non-coding RNAs that suppress gene expression following transcription.  
Demonstrated to be important to cancer, metabolic disease, and even viral infection, they may 
represent potential drug targets in several human diseases20.  There is reason to suspect that 
aberrant expression of specific miRNAs may be associated with certain types of male infertility.  
First, single nucleotide polymorphisms (SNPs) at miRNA binding sites have been reported in 
association with idiopathic male infertility.  Relationships have also been demonstrated between 
male infertility and SNPs in genes essential to miRNA biogenesis.  Additional research of 
miRNAs offers potential in finding novel molecular genetic causes, as well as future targets for 
gene therapy21. 
The next three classes of experimental gene therapy are artificial chromosomes, circular 
auto replicating DNA episodes, and electroporation.  Of these three, artificial chromosomes are 
not technically feasible at this time for infertility therapy.  Electroporation, however, has been 
successful in transfecting Sertoli cells; it involves an electric field being applied to cells in order 
to increase permeability in the cell membrane, which allows DNA to be introduced into the cell.  
In 2002, Yomogida et al.22 used this technique to rescue spermatogenesis in infertile mice due to 
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damaged Sertoli cells with a mutated stem cell factor (SCF) cytoplasmic domain resulting from a 
splicing defect.  Although the Yomogida and colleagues conclude that this technique shows 
promise as a somatic gene therapy for male infertility, they recognize that a major obstacle to its 
utility in infertility treatment is the reduced viability of treated germ cells and the instability of 
transfected genes22.  The final of the three, circular auto replicating DNA episodes, has been used 
in mice to obtain stable transgene expression without genomic integration.  This technology 
involves episomally transfecting spermatogonia stem cells in vitro, allowing clonal expansion, 
and then transfecting stem cells back into the host.  This is a promising approach for gene 
therapy, but germ cell transfection has shown limited success17.    
The final type of prospective gene therapy for male infertility, which was chosen for this 
project, is lentiviral gene therapy.  Lentiviral vectors have been successfully utilized to re-
establish gene function in mouse models and clinical trials for multiple human diseases.  It has 
also been successfully used to restore fertility in male mice.  Although the cause of 
spermatogenetic failure in most cases of male infertility remains idiopathic, and no treatment to 
improve spermatogenesis is available to these men, more investigations on the genetics of 
spermatogenesis and male infertility along with the development of gene therapy may offer 
significant advances for treatment23. 
1.1.4 Lentiviral Gene Therapy 
Lentiviral vector gene therapy has been shown to be an effective tool for ex vivo and in vivo 
transfer with several research groups reporting that it can be used to treat or even cure diseases.  
4; 24.  The first clinical trial using lentiviral vector gene therapy was begun in June 2012, and 
since that time there are more than 300 ongoing or approved trials25.  These include treatment of 
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single gene diseases such as X-linked cerebral adrenoleukodystrophy, Sickle cell anemia, 
Wiskott-Aldrich syndrome, metachromatic leukodystrophy, X-linked chronic granulomatous 
disease, and several others.  There are also trials to test the utility in certain cancers, Parkinson’s 
disease, and Stargardt macular degeneration4; 24.   
One group of researchers even reports restoring spermatogenesis in infertile male mice.  
Their work involved c-kit ligand (steel factor) deficient mice5.  This group injected a lentivirus 
into the seminiferous tubules to transfect Sertoli cells with a functional c-kit ligand.  
Spermatogenesis was restored (low levels), and the viral vector was not seen in germ cells.  They 
were also able to use the sperm of these mice for successful intracytoplasmic sperm injection, 
and offspring did not inherit the transgene.  Although the vector therapy appeared to be 
successful, there were limitations to this study.  First, the treated male mice could not generate 
pups by normal mating.  The group speculates on several plausible explanations. These include:  
the number of Sertoli cells transduced by the lentiviral vector might not have been high enough, 
the mating period might not have been long enough, and the fact that the CMV promoter was 
used in the study, which may not accurately model natural c-kit ligand expression.  Also, there is 
unfortunately no steel factor homologue known in humans.  There are, however, functionally 
similar genes important to Sertoli cell function in humans such as claudin-11, protein C inhibitor, 
and tyro-3 families that are necessary for spermatogenesis5. 
Much research is required to achieve the full potential of lentiviral gene therapy.  The 
primary concerns at this point regarding therapy in humans involve safety.  The major safety 
concerns are the formation of replication competent retroviral vectors, disruption of normal gene 
function upon integration of the virus into the host genome (such as cancer development caused 
by insertion of the vector into an oncogene), and that most lentiviruses are derived from a known 
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human pathogen, HIV.  Safety efforts made so far have involved splitting the vector by 
expression cassettes, the use of self-inactivating vectors, using low volumes of viral vectors, and 
homology reduction between viral elements4.   
Beyond the demonstrable success in treating disease in mouse models, there are 
numerous advantages in using lentiviruses as a medium for gene therapy.  First, one advantage to 
lentiviruses over another commonly used vector, the adenovirus, is that the adenovirus cannot 
integrate into the host DNA.  Therefore, the gene of interest is not replicated upon cell division17; 
meaning the patient may need numerous viral injections to achieve a lasting effect.  Furthermore, 
adenoviruses cannot infect germ cells, while lentiviral vectors are not affected by epigenetic 
silencing during development, and have the capacity to infect dividing and non-dividing cells26.  
Compared to other viral vectors the lentivirus enables long-term stable expression of the 
transgene with low immunogenicity27.  Lastly, integration into the host genome once caused a 
great concern for the development of cancer as a side effect of lentiviral therapy.  However, 
although lentiviral vectors target active transcription units, for the most part they are integrated 
randomly throughout the genome.  On the other hand, γ-retroviral vectors interact preferentially 
with active host cell promoters and enhancer-regions that are enriched in transcription factor 
binding sites (TFBS) due to their integrase and LTRs. These regions are often rich in cancer – 
related genes.  Therefore triggering cancer development is of less concern for lentiviral gene 
therapy, and this in part might explain the difference in safety profiles of the two vector types28.  
Although lentiviral vector therapy presents a promising means for gene therapy, additional 
results from patients and animal models treated with lentiviral vector gene therapy are needed 
before solid conclusions can be drawn concerning the safety of the vector system28.  
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1.1.5 Yatsenko Lab Research Efforts 
Dr. Yatsenko of Magee-Womens Research Institute and Foundation (MWRI) is working together 
with researchers and physicians at Magee-Womens Hospital to identify novel genetic causes of 
male factor infertility.  The focus of the research is on idiopathic azoospermia and 
oligozoospermia.  At this point, three primary methods of gene discovery are utilized in the 
affected population to identify novel variants that may be associated with infertility.  These 
include array comparative genomic hybridization (aCGH) (genome wide as well as an X 
chromosome array designed to identify variants associated with male infertility), RNA 
expression studies, and familial-based whole exome sequencing studies.  These projects involve 
recruiting appropriate research subjects, performing RNA expression studies, aCGH, or whole 
exome sequencing on their DNA samples, identifying potential causative variants of infertility, 
and eventually developing mouse models that can be used to validate and study these candidate 
genes. My role in these research efforts has been in recruitment, performing essential laboratory 
bench work, identifying candidate genes for a gene therapy pilot project, and helping manage the 
mouse colony for this gene therapy pilot project.   
I recruit subjects primarily through the reproductive endocrinology and infertility (REI) 
clinic, and urology clinic at Magee-Womens Hospital of UPMC, but I have also made efforts to 
expand the recruitment base for the male infertility research study.   The main subjects of interest 
are men diagnosed with idiopathic, nonobstructive azoospermia or oligozoospermia.  To 
ascertain information about the patient’s medical and family history, I ask them to fill out a 
questionnaire, and take a pedigree.  Results of their semen analysis are also reviewed. 
To expand the recruitment base of the study, I advertised the research through online 
media, social networks, and other infertility clinics in the greater Pittsburgh area.  These efforts 
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of expansion also required the institutional review board’s approval.  First, I wrote a section 
describing the study, and how to contact the group if interested in participating.  This section, 
posted through online mediums, required IRB approval to determine whether it was 
appropriately advertising the study, free of coercion, and that it would not be biased toward a 
specific ethnic or socioeconomic group.  Areas the advertisement was posted online included 
Facebook groups for infertility and male infertility.  I also posted it onto other forums meant for 
couples struggling through infertility, as well as forums that were specific to male infertility.  
Lastly, the advertisement was posted and distributed by infertility support groups, hotlines, and 
other reproductive and infertility clinics in the Pittsburgh area.  Through this expansion, several 
individuals were recruited outside of the clinics within Magee-Womens Hospital, and we 
received interest in the study from men throughout the United States.   
Recently, myself, Alex Yatsenko, MD, PhD, and Kyle Orwig, PhD, began efforts to 
perform an experimental gene therapy on infertile male mice as proof-of-concept that this may 
serve as a possible treatment for restoring spermatogenesis and infertile men.  The goal of this 
project was to restore spermatogenesis in viable male mice with low or absent spermatogenesis 
due to a gene defect in Sertoli cells.  At this point, although there are likely numerous targets for 
gene therapy in germ cells, the intention of the project is to focus on somatic cells, e.g. Sertoli 
cells, to avoid ethical concerns of altering the germ line, which would be unacceptable for human 
therapy. In the long term, if the gene therapy is successful, we hope to repeat the therapy on a 
mouse line with a single gene knockout of a candidate gene identified in his study population of 
infertile males.  This would have great potential for translation in the clinical setting, as it would 
show that spermatogenesis may be restored in men previously incapable of reproducing even 
with available treatments for infertility. 
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1.2 SPECIFIC AIMS 
This project consists of three specific aims.  The first aim involved the identification of candidate 
genes for the gene therapy via bioinformatics databases and literature review, along with data 
mining of our study population.  The second aim was to characterize the Dnaja1 gene, and to 
replicate data found in the available literature.  The final aim was to develop the viral vector and 
perform gene therapy to restore spermatogenesis in viable, infertile male mice.   
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2.0  METHODS 
2.1 IDENTIFYING CANDIDATE GENES 
2.1.1 Candidate Gene Selection Criteria 
The purpose of this research was to identify potential gene therapy targets for Mus musculus 
knockouts.  Figure 1 shows the search and filtration process I used to choose candidate genes.  
At the outset of the project, it was decided that ideal candidate genes would have known mouse 
phenotypes exclusively related to male infertility, including one or more of the following: 
azoospermia, asthenozoospermia, teratazoospermia, and/or oligozoospermia.  This would model 
isolated, idiopathic infertility in human males.  Candidate genes must also have expression 
profiles limited to the testis and reproductive organs.  This criterion was chosen in order to avoid 
the possibility of the gene knockouts causing severe phenotypes other than infertility, as well as 
the possibility of the gene therapy having effects beyond the reproductive system.  Furthermore, 
because the goal was to target somatic cells, infertility in male mice must be caused by a primary 
defect in Sertoli cells due to a mutated gene that is expressed in Sertoli cells, rather than germ 
cells.  Because the gene therapy would be administered at approximately day 15 of the mouse’s 
life cycle, the infertility phenotype must also be due to an error in spermatogenesis, rather than a 
developmental defect.  Realistically, severe developmental abnormalities such as testicular 
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agenesis, absence of the vas deferens, etc. could not be repaired by a gene therapy given to a 
mature mouse.  On the other hand, gene therapy may be more likely to repair an error at a single 
step in spermatogenesis or aberrant interaction between Sertoli cells and germ cells.  Lastly, due 
to the laboratory’s limited capacity to develop mouse lines, as well as time constraints of the 
project, the ideal candidate gene would have an available live mouse line ready for order through 
a mouse repository, such as Jackson Laboratories, and antibodies available through commercial 
laboratories.  In the long term, however, if this pilot project is successful, we may perform the 
clustered regularly interspaced short palindromic repeats (CRISPR) technique ourselves to 
knockout future candidate genes in mice of their own.  The criterion of known testis – specific 
expression was later relaxed in order to accommodate the gene selected for the first experimental 
gene therapy.     
 
 
Figure 1.  Candidate gene selection 
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2.1.2 Bioinformatics Databases and Literature Review 
I took three primary approaches to identify and filter candidate genes.  First I performed a raw 
search in the Mouse Genome Informatics Database (MGI) using terms related to male infertility, 
particularly “azoospermia” and then cross referenced this list with expression profiles provided 
by NCBI’s UniGene, BioGPS, and GeneCards.  The next approach involved beginning with 
genes known to be expressed in Sertoli cells, and then performing searches on MGI and the 
available expression profiles.  Lastly, I performed similar searches for genes with variants 
identified in Dr. Yatsenko’s study population of infertile males discovered through microarray, 
exome, and RNA expression studies.   
 
Filtering Genes with male infertility phenotype 
 
I began the search for candidate genes using the Mouse Genome Informatics (MGI) 
database hosted by The Jackson Laboratory.  This database provides open access to searchable 
data on the genetics of laboratory mice to facilitate the study of human health and disease29.  By 
entering the search term “azoospermia” in the Mammalian Phenotype Browser query 242 genes 
associated with azoospermia in mice were identified.  Of these genes, I eliminated those that 
included phenotypes not related to fertility, e.g. more severe phenotypes such as embryonic 
lethality, heart defects, etc.  I then filtered genes with phenotypes exclusively related to infertility 
based on their expressed sequence tag profiles in Mus musculus on NCBI’s UniGene.  I included 
genes with expression limited to the testis, or with high testis expression and relatively low 
expression in other tissue as candidate genes.   
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 Due to time constraints for this project, our laboratory was not able to develop mouse 
lines with these genes nullified.  Therefore, I searched The Jackson Laboratory’s JAX Mice 
Database for available null and knockout mouse lines30.   
 For the final step in identifying candidate genes, I searched for available antibodies that 
would be reactive in Mus musculus and could be used for immunohistochemistry assays.  I used 
the Antibody Resource website to identify vendors of the necessary antibodies.  All of the genes 
identified through the MGI/UniGene/JAX search had available antibodies corresponding to the 
proteins they transcribed.   
 
Filtering genes expressed in Sertoli cells 
 
To avoid ethical concerns of altering the genetic makeup of sperm cells, one goal of this 
project was to perform gene therapy on targets in somatic cells.  Because Sertoli cells can 
strongly influence sperm production, but are not considered part of the germline, another method 
of identifying candidate genes was to begin by searching for genes known to be expressed 
primarily in these cells.   
 I utilized three primary publications to identify genes differentially expressed in sertoli 
cells in the presence of gonadotropins. These articles included: “Oligonucleotide Microarray 
Analysis of Gene Expression in Follicle – Stimulating Hormone – Treated Rat sertoli Cells,” 
“The Biology of infertility: research advances and clinical challenges,” and “RiboTag Analysis 
of Actively Translated mRNAs in Sertoli and Leydig Cell In Vivo,” the last of which claimed to 
have a comprehensive list of differentially expressed genes in sertoli cells comprised of several 
thousand genes15; 31; 32.  This was developed utilizing next – generation sequencing coupled with 
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a RiboTag approach.  The list of genes expressed specifically in Sertoli cells in both prepubertal 
and adult mice was coined the “SC translome”.  
 I first entered these genes into the MGI mouse phenotype query, and then searched those 
genes that were associated with male infertility phenotypes using UniGene’s expressed sequence 
tag profiles, as well as BioGPS and GeneCard’s expression profiles.  I include genes that were 
associated with male infertility, and with expression restricted to the testis as candidate genes.   
2.1.3 Yatsenko Lab Data Mining 
The final method of searching for candidate genes I used involved mining previous data 
produced by RNAseq, whole exome, and aCGG performed on Dr. Yatsenko’s study population 
of male infertility patients.  From these studies, several variants had been discovered in genes 
that may be related to infertility.  Unfortunately, all of these genes were expressed in germ cells.  
One gene, Cib1, did appear to be a promising candidate.  Cib1 has been found to be essential in 
mouse spermatogenesis.  And although it is expressed in germ cells as well as Sertoli cells, the 
expression is much higher in Sertoli cells.  Therefore the primary defect causing azoospermia in 
otherwise healthy mice may be due to aberrant differentiation of Sertoli cells.  Cib1 homozygous 
male knockout mice are sterile due to disruption at the haploid phase of spermatogenesis.  
Expression of Cib1 is not testes specific according to NCBI’s expressed sequence tag profile, but 
the only phenotypes known in Cib1 knockouts are related to reduced spermatogenesis33.    
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2.2 DNAJA1 CHARACTERIZATION  
2.2.1 Dnaja1 Expression Profile 
I utilized RT-PCR to confirm the expression profile of the Dnaja1 gene in mice.  First, a cDNA 
library from mRNA in multiple mouse tissues was developed using the epicentre kit from 
illumina®. Tissues included the fetal brain, fetal liver, cerebellum, thymus, spleen, placenta, 
lung, uterus, heart, liver, kidney, ovary, skeletal muscle, small intestine, epididymis cauda, 
corpus, caput, and whole epididymis, interstitial cells, seminiferous tubules, and testes.  A 
portion of this cDNA panel had been developed previously, but there were several tissues for 
which I needed to generate new cDNA. I designed Dnaja1 PCR primers using the University of 
California Santa Cruz genome browser and optimized at various temperatures using mouse testes 
tissues and a gene known to have ubiquitous expression in mice as a control, Gapdh.  Following 
primer optimization, I selected one pair of primers for the RT-PCR expression panel. The 
primers were manufactured by Integrated DNA Technologies.  Dnaja1 primer sequences were: 
Dnaja1_RT2-2-F 5’-AGTCATCACCTCTCATCCAGGT-3’ and Dnaja1_RT2-2-R 5’- 
GTCCACCAGTTCTACCTGATCC-3’.  The PCR program was as follows:  95oC for five 
minutes [98oC for 25 seconds, 61oC for 25 seconds, 72oC for 25 seconds] X 30.  Gapdh was also 
used as a positive control.  I ran the PCR products on gel electrophoresis and photographed them 
under ultra violet light.   
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2.2.2 Immunohistochemistry 
I performed the immunohistochemistry with the assistance of Kayla Golnoski, MS and Archana 
Kishore, PhD.  The testes of wildtype mice were fixed in Bouin’s fixative at 4oC for 12-16 hours, 
dehydrated, and embedded in paraffin block.  Sections (5 μm thick) were cut and mounted onto 
poly-lysine-coated slides. Microwave antigen retrieval was employed as described previously34. 
After blocking, an aliquot of 100 μl primary antibody diluted at 1:200 was applied to each 
section and incubated at 4oC overnight. Incubation with secondary antibody and visualization of 
positive cells were performed using Vectastain Elite-kit (Vector Laboratories, Inc., Burlingame, 
CA) according to the manufacturer’s instructions. Preimmune serum was used in control 
sections.  A monoclonal anti – Dnaja1 antibody was used.  Biotin conjugated anti – mouse was 
used as a secondary antibody.  Images were captured by Zeiss microscope equipped with 
AxioCam MRc5 camera system. Dnaja1 antibody was developed by abcam® using fusion 
protein corresponding to N terminal amino acids 1 – 179 of Human HDJ2. 
2.2.3 Sequence Conservation Analysis 
I analyzed the conservation of genomic and protein sequence between human and mouse 
Dnaja1/DNAJA1 utilizing the Multiple Sequence Alignment tool by CLUSTALW, which is 
available for use online.  First, genomic and protein sequences for Homo sapiens and Mus 
musculus Dnaja1  were obtained from NCBI’s gene database and saved into a Word Document.  
I then entered these files into the CLUSTALW tool which read and analyzed the sequences 
conservation of sequence between species. 
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2.3 LENTIVIRAL THERAPY 
2.3.1 Breeding Strategy and Dnaja1 Knockout Mice Generation 
Archana Kishore, PhD, and I developed and managed the Dnaja1 mouse knockout line.  
Breeding to obtain two to three male Dnaja1 homozygous knockout mice began with the 
ordering of 2 Dnaja1 heterozygous knockout males, and one heterozygous knockout female.  
The knockout mutant had been generated at Jackson Laboratories by the Knockout Mouse 
Phenotyping Program (KOMP2).  To produce the mutation, a beta-galactosidase-containing 
cassette disrupts the Dnaja1 gene in this strain.  The insertion of Velocigene cassette ZEN-Ub1 
created a deletion of size 9258bp between positions 40670749-40680006 of chromosome 4 
(Genome Build 37) and subsequent Cre expression excised the neomycin selection cassette. The 
expected litter size was about eight mice.  Therefore each round of breeding should have produce 
roughly 2 wildtype mice, 4 heterozygotes, and 2 homozygous knockouts.  Wildtype mice were 
sacrificed, while heterozygous mice were either sacrificed or used for maintaining the Dnaja1 
knockout line.  Homozygous knockout males were to be used for the lentiviral vector injection.  
The breeding strategy is shown in Figure 2 below.   
For the knockout mice, the strain of origin is C57BL/6NTac, as previously used by 
Terada and colleagues6.  They generated their Dnaja1 knockout mice using an embryonic stem 
cell line generated with a positive/negative-targeting vector.  They then used neomycin 
phosphotransferase gene to create a deletion of the J domain and the G/F-rich domain (exons 2-
3).   
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Figure 2. Mouse breeding strategy 
2.3.2 Mouse Genotyping 
I genotyped mice using the following PCR primers designed by Jackson Laboratories: Wildtype 
Forward-5’-TTCTTCTGGTGAACTTTGGAG-3’, Wildtype Reverse ACCATTCCTGGT 
CCAATCTG-3’, Mutant reverse-5’-CCCATAGCTTAACAATGAAGGG – 3’, Mutant Forward-
5’-CGG TCG CTACCATTACCAGT-3’.  These primers were designed to produce one PCR 
product for each allele.  Thus, wildtype and homozygous knockout mice would show one unique 
band on gel electrophoresis, while heterozygotes would show two bands.  PCR was performed 
on mouse tail DNA using the amfisure® kit.  To isolate DNA from the mouse tail, tail clippings 
were first placed in 1.2 ml microfuge tubes.  0.5 ml of 50 mM NaOH was added to each tube.  
Tubes were heated at 100oC for 30 minutes.  Following incubation tubes were shaken three to 
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four times, and then placed at 4oC for 10 minutes. 1M Tris-HCL, pH 8.0 was added and tubes 
were vortexed, then centrifuged at 21, 000 rcf for 10 minutes.  Supernatant was transferred to 
fresh tube following centrifugation.  The PCR program was set at 93oC for 3 minutes, followed 
by 35 cycles of 94oC for 30 seconds, 60oC for 25 seconds, and 72oC for 30 seconds.   Product 
was run on gel electrophoresis and viewed under ultraviolet light.   
2.3.3 Lentiviral vector development 
2.3.3.1 Vector development 
The vector, shown in figure 3 below, used was designed and developed by Dr. Yi Sheng working 
in Dr. Kyle Orwig’s laboratory.  The vector was constructed with the pC – FUW lentiviral 
backbone using methods previously described 35; 36.  The three important functional elements in 
the vector were the EF1a promotor (a ubiquitous promotor), enhanced green fluorescent protein 
(eGfp) to tag expression of the vector, and the Dnaja1 gene.  The eGfp and Dnaja1 gene were 
inserted as a single construct in order to avoid the possibility of EGFP2 expression with a lack of 
DNAJA1 expression.  The Dnaja1 cDNA construct was manufactured by Transgene.  First, 
Dnaja1 cDNA was amplified by PCR with the primers: Dnaja1-F 5’-
GGTACCGTCGACATGGTGAAAGAAACCACTTACTAC-3’ and Dnaja1-R 5’– 
GAATTCGGATCCTTAAGAGGTCTGACACTGAACG-3’.  The EGFP-T2A fragment was 
isolated from pEGFP-T2A-mCherry via Nhel/SaII digestion and gel purification.  These two 
fragments were inserted into the SpeI/EcoRV sites of pEF-ENTR A (addgene 174527), followed 
by transfer of EF1 promoter and EGFP2-Dnaja1 into pC-FW-DEST via Gateway LR 
recombination (Life technologies).  The lentiviral vector was produced according to Virapower 
Lentiviral Expression System (Life technologies).   
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The replication – deficient lentiviral vector contains a self-inactivating 3’UTR and a CMV enhancer 
replacing the U3 region of the 5’ UTR.  WRE: woodchuck hepatitis posttranscriptional regulatory 
element.  HIV-1 flap is a viral element that initiates transduction.  The universal promotor EF1a was 
used.  ∆3 represents a deletion rendering this region inactive.  The vector was constructed with the pC -
FUW lentiviral backbone using methods previously described 35; 36. 
 
Figure 3. Lentiviral vector 
 
2.3.3.2 Confirmation of Dnaja1 cDNA insertion 
Yi Sheng, MD, PhD, confirmed that the Dnaja1 cDNA was successful via PCR and gel 
electrophoresis.  Eight bacterial colonies were transfected with the EF1a-EGFP-Dnaja1 lentiviral 
vector construct.  The vector was then linearized with an EcoRI restriction digest followed by 
amplification by PCR.  This product was run on gel electrophoresis and photographed under 
ultraviolet light.   
 
2.3.3.3 Confirmation of GFP and vector expression in testes 
Yi Sheng, MD, PhD, confirmed vector expression in the testes via GFP studies.  Mice were 
anesthetized and testes were exposed.  The lentiviral vector, mixed with one tenth of 0.4% 
 25 
trypsin blue dye was injected into seminiferous tubules through the efferent duct of one side of 
the testes, while the vehicle (DMEM media) was injected into the other side of the testes.  The 
testes were removed 72 hours after injection, and observed under epifluorescent microscopy at 
10x and 20x views.   
2.3.4 Vector Injection Strategy 
Kyle Orwig, PhD, had previously developed a methodology for lentiviral vector injection.  The 
lentiviral EF1a-EGFP construct is injected into the homozygous knockout male mouse testes at 
day 15-18 of the life cycle.  The mice are then allowed to mate with the females to determine if 
they are fertile or infertile.  After the mice are given sufficient time for breeding the experimental 
male mouse is removed and the testes will be used for semen analysis, histological analysis, and 





3.0  RESULTS 
3.1 SPECIFIC AIM 1 
Filtering genes with azoospermia mouse phenotype 
I identified several genes by searching “azoospermia” and “male infertility” on MGI, 
eliminating genes with phenotypes unrelated to male infertility, and by cross-referencing these 
genes with expression profiles on NCBI’s Unigene, BioGPS, and Genecards, that were expressed 
exclusively in mouse testes, and that were known to cause isolated male infertility in mice.  
However, most of the genes were expressed in the germ line, rather than Sertoli or other somatic 
cells.  Because these genes show germline-specific expression, they were not considered as 
candidates for experimentation at this point.  This project aimed to avoid altering the germline 
due to ethical concerns, and it was not anticipated that germ cells would be transfected by this 
virus vector.  However, these genes may be used in future experimentation since they do 
represent potential causes of isolated infertility in men, and may be acceptable targets of gene 
therapy if germline gene therapy is ever considered accepftable for use in the clinical setting.  A 
brief description of selected genes identified via this method is provided.  The following genes 




Table 1. Known male mouse infertility phenotype in germ cell expressed genes 
Gene Isolated Male infertility MP Testis – Limited Expression 
Catsper1 •   •  
Mei1 •    
Mov10l1 •   •  
   
Piwil1 •   •  
Spo11 •   •  
Stag3 •     
Stra8 •   •  




Catsper1 transcribes a Ca2+ cation channel located specifically in the principle piece of 
the sperm tail.  Targeted disruption caused male infertility in otherwise unaffected mice, with 
markedly decreased sperm motility37. JAX has a cryopreserved – ready for recovery null mouse 
line for Catsper1 and there are available antibodies for the transcribed protein (Cation channel 
sperm – associated protein 3 antibody).  
 
Mei1 
The phenotype of Mei1 mouse knockouts is reminiscent of Sertoli-cell-only syndrome in 
humans 38.  The EST profile for this gene, which encodes meiosis inhibitor protein 1, shows high 
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testis expression, and low expression in the brain, eye, and bladder.  There is a knockout mouse 
line that is cryopreserved and ready for recovery through JAX. 
 
Mov10l1 
Mov10l1 is necessary for a group of noncoding RNAs that function as an endogenous 
defense mechanism against transposable elements to function properly.  Mov10l1, which is 
exclusively expressed in germ cells, is has been found to play a role in silencing retrotransposons 
in mouse germ cells.  Mouse knockouts were essentially healthy, and displayed Sertoli-cell-only 
phenotypes 39. The EST profile for this gene shows high testis expression, and low expression in 
the heart and ovaries.  There is a JAX knockout mouse line available.   
 
Piwil1 
Piwil1 initiates transposon silencing via DNA methylation in the embryonic germline of 
male mice and is expressed in postnatal germ cells 40.  Phenotypes in mouse knockouts include: 
arrest of spermatogenesis, male infertility, decreased testis weight, azoospermia, abnormal male 
germ cell morphology, and arrest of male meiosis.  There is a JAX knockout line available, and 
Piwil1 was also in our RNAseq dataset. 
 
Spo11 
Knockouts of Spo11, which encodes meiotic recombination protein SPO11, cause meiotic 
arrest at the spermatocyte stage.  Smagulova et al. 2013 found that the SPO11 protein causes 
double stranded DNA breaks in “recombination hotspots” in order to elicit recombination41. All 
phenotypes shown in mice through MGI and literature review are related to fertility, and include 
 29 
azoospermia.  The EST profile for this transcript shows high testis expression, and low thymus 
expression, and there is a JAX mouse line available.   
 
Stag3 
 Stag3 codes for a cohesin that is specifically involved in germ cell meiosis.  
Spermatogonia, Sertoli, and leydig cells were all apparently normal in mouse knockouts.  The 
only phenotypes identified in these knockouts were absent oocytes, and azoospermia.  The EST 
profiles shows high expression in the testis, and low expression in a limited number of other 
organs.  There is a JAX knockout line available.   
 
Stra8 
Stra8 homozygous knockouts were generally healthy, with phenotypes similar to Sertoli-
cell-only syndrome in humans.  Stra8 does not show expression in Sertoli cells, but the EST 
profile shows expression specific to the testis.  There is a JAX mouse line available.  STRA8 
protein may play a role in chromosome pairing in spermatocytes42. 
 
Sycp1  
Sycp1 mouse knockouts were generally healthy with azoospermia.  The EST profile 
shows expression in the testis and ovaries only, and a JAX knockout line is available.  SYCP1 
protein is involved in the construction of transverse filaments, which are responsible for 







Filtering genes expressed in Sertoli cells 
 
Using this search method finding genes with phenotypes restricted to male infertility, as 
well as genes with expression limited to the testis, was more difficult and less prolific.  I first 
identified genes expressed in Sertoli cells via literature review.  I then cross – referenced that list 
with MGI and expression databases (Unigene, Genecards, and BioGPSS) to identify candidates 
with isolated male infertility phenotypes in mice and testes-specific expression.  The genes 
discovered will be discussed here, with focus given to the Dnaja1 gene, which was eventually 
the gene selected for experimentation due to its known phenotype, and the availability of live 
mouse knockouts available for order through the Jackson Laboratory’s mouse repository.  Some 
of these genes had available frozen mouse embryonic stem cell knockout lines through JAX, 
however, developing a live mouse knockout line from these cells (in an experienced laboratory, 
and assuming each part of the process is successful) would take at least six months, which was 
beyond the time I had available to complete the project.  The following genes are summarized in 














Table 2. Sertoli cell expressed genes with known male infertility phenotype in mice 
Gene Male infertility MP Testis – Limited Expression 
L1cam •    
Egr1 •    
SSeCKS •     
   
Cyp17a1 •   •   
Dhh •   •   
Dmrt1 •   •   
Lhcgr •   •   
Serpina 5 •   •   
Dnaja1 •    
Sox8 •    
   
Slc9a2 •   •    
Wt1 •   •   
Nr0b1 •   •   
Inha •   •   
Prnd •     
Amhr2 •   •   
Pcyt1b •    •   
Amh •     




 Of the genes that were shown to have mouse knockouts with male infertility and 
expression relatively limited to the testis, only three were associated with azoospermia in mice.  
These were Dhh, Wt1, and Amhr2.  Unfortunately, each of these genes has shown deficiencies in 
several systems other than the male reproductive system in mouse knockouts, and their 
expression is not limited to the testis.  Three genes, Lhcgr, Dnaja1, and Prn, displayed 
oligozoospermia in null mice.  Lhcg and Dnaja1 knockout mice also displayed other phenotypes 
such as postnatal growth retardation and decreased body weight.  Lhcg mice showed enlarged 
kidneys as well.  Prnd mouse knockouts only displayed deficiencies related to the male 
reproductive system, including oligozoospermia, asthenozoospermia, and teratozoospermia.  
According to the EST profile for mice on NCBI’s UniGene, Prnd is ubiquitously expressed in 
mice.  However, the accuracy of this profile may be questioned since the human expression 
profile shows high expression in the testis, and low expression in only the eye, heart, bone 
marrow, and prostate, and because the only phenotypes shown in mouse knockouts on MGI are 
related to male infertility.  There is no available Prnd mouse line from JAX.  
 Four other genes displayed asthenozoospermia in mouse knockouts.  These include 
Cyp17a1, Serpina5, Dnaja1, and Sox8.  Cyp17a1, Dnaja1, and Sox8 included severe phenotypes 
other than male infertility, including embryonic lethality, postnatal growth retardation, and sex 
reversal. Serpina5, on the other hand, is only expressed in the testis and ovaries, and only 
phenotypes involved in the reproductive system were observed in mice.  Unfortunately, there is 
no JAX line available for Serpina5.  Dnaja1 is a chaperone primarily expressed in sertoli cells.  
The two phenotypes of concern shown in Dnaja1 mouse knockouts were postnatal growth 
retardation, and decreased body weight.  There is an available mouse line through JAX as well.   
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Dmrt1 is an ancient, zinc finger-like DNA-binding motif that is gonad specific and 
sexually dimorphic expression pattern.  It is expressed in Sertoli cells, and is necessary for 
maintaining male germ cells, but there is no mouse line available from JAX.   
Because the search criteria for Sertoli-cell expressed genes was too restrictive, our 
criteria was relaxed in order to select at least three to four genes to study.  We chose to include 
genes expressed in Sertoli cells whose mouse knockouts showed male infertility related to sperm 
maturation or function, including azoospermia, oligospermia, morphology, motility, and oocyte 
binding.  Also, rather than maintaining the requirement for these genes to have testis specific 
expression based on NCBI’s EST profile, genes were included provided that their knockout lines 
produced viable, infertile males.  Other known mouse phenotypes in knockouts were disregarded 
assuming they did not severely decrease the viability of the mice.  Furthermore, at this point 
there is no interest in attempting gene therapy on the genes expressed in germ cells.  The 
reasoning for this is twofold.  First, there are several ethical concerns involved with gene therapy 
on germ cells due to the potential of affecting future generations.  Because of this, performing 
gene therapy on germ cells in mice does not translate well to clinical utility, since gene therapy 
on human germ cells is not feasible/ethical/legal/etc.  Secondly, it is possible that the virus 
vectors will not matriculate into germ cells, since their phagocytic potential is much lower than 
Sertoli cells. 
 Originally, the genes selected for experimentation were Akap9 (however no mouse line 
was available through any searched repositories) Prnd, Dnaja1, Dmrt1, Dhh, and Serpina5.  A 
brief summary of these genes, and potential alternative candidate genes are given below.  Dnaja1 
was ultimately chosen for experimentation because of the phenotype described by Terada and 
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colleagues in 20056 and due to the availability of a live knockout line being maintained by The 






Dhh is a Sertoli cell-expressed gene that regulates early and late stages of 
spermatogenesis.  Male Dhh knockout mice are viable, yet infertile due to lack of mature sperm.  





Dmrt1 is expressed in pre-meiotic germ cells and in Sertoli cells in mice. Serving  
important functions in these cells,  it is necessary for the radial migration of germ cells to the 
periphery of seminiferous tubules, and for postnatal differentiation in Sertoli cells44. 
 
Prnd 
Prnd is a gene that codes for the prion protein duplet (DPL) protein.   Prnd knockouts in 
mice resulted in male infertility. DPL protein is expressed in late stages of spermiogenesis.  
Behrens and colleagues found that “spermatids of Dpl mutants were reduced in numbers, 
immobile, malformed and unable to fertilize oocytes in vitro.”  They concluded that “Dpl 





Serpina5 mouse knockouts appear to be healthy, but males are sterile. Uhrin and 





Akap9 has been found to play an important role in coordinating regulation of Sertoli cells 
in the testis in a tissue-specific manner.  In Akap9 knockout mice, gap and tight junctions 
essential for blood-testis barrier (BTB) organization are disrupted.  Connexin43 and zona 
occludens-1 are also improperly localized in Akap9 mutant testis.  Male knockout mice are 
viable, but infertile.  Phenotypes include azoospermia, oligozoospermia, globozoospermia, and 
decreased testis weight.  The expressed sequence tag profile shows that expression is nearly 
ubiquitous, but phenotypes shown by MGI contradict this47.  
 
Pvrl2 
Although Pvrl2 homozygous knockout male mice produce normal amounts of motile 
spermatozoa, scanning electron microscopy performed on these mice showed deformities of the 
spermatozoan head and midpiece.  This gene is expressed exclusively in Sertoli cells, but 
unfortunately there is no line available on JAX. Mouse production is planned according to IMPC 
search results.  EST does not show testis-specific expression.  This might be a priority for 




Sox8 null mice were seen to have male infertility that progressed with age. Null males 
occasionally produced small litters at young ages. SOX8 protein is produced by Sertoli cells.  
Spermatogenesis abnormalities that have been observed in null males include loss of 
spermatocytes and round spermatids, disorganized spermatogenesis, and absence of spermiation. 
O’Bryan and colleagues also observed abnormal motility of sperm within the epididymides, and 
that SOX8 regulates Sertoli cell function.  The protein is also required for the cytoarchitectural 





Etv5 is a potential future candidate gene discovered via literature review following the 
initial search methods.  In 2013, O’Bryan et al. reported male infertility in male mice with a 
missense mutation in ETV550.  The mutation in this transcription factor led to embryonic and 
perinatal lethality, poor growth, renal asymmetry, and polydactyly.  In 2005, Chen et al. showed 
that this gene displays Sertoli cell-specific expression51.  They also demonstrated that ETV5 is 
necessary for regeneration of spermatogonial stem cells.  Mice with targeted disruption display 
progressive germ cell depletion and Sertoli cell-only syndrome by age 8 weeks.  Sertoli cells 
showed alterations in secreted factors known to regulate the hematopoietic stem cell niche.  The 
mutation generated by O’Bryan and colleagues was located in exon 12, and it caused a premature 
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stop codon at position 412 in the ETS DNA binding domain.  ETV5 therefore appears to play a 
role in several aspects of development beginning in the embryonic state.50; 51.   
 
Dnaja1 
Of the above genes, Dnaja1 was determined to be a viable candidate gene based on a 
study performed by Terada et al. in 2005, and was selected for the pilot gene therapy because it 
was the only one of these candidates for which there was an available live mouse maintained by 
the Jackson Laboratories6.  Other genes were unavailable through JAX, or only available as 
frozen stem cells.  Generating a live mouse line using these cells would require several months 
of labor.   Alternate genes mentioned may be used for future projects pending the success of the 
Dnaja1 effort. As mentioned previously, Dnaja1 is a chaperone primarily expressed in Sertoli 
cells.  Although growth retardation and decreased body weight have been observed in Dnaja1 
mouse knockouts, the mice are otherwise viable, which was expected to allow the attempt of 
viral vector therapy.   
Terada and colleagues reported that “loss of Dnaja1 in mice led to severe defects in 
spermatogenesis that involved aberrant androgen signaling.”  Also “transplantation experiments 
with green fluorescent protein-labeled spermatogonia in Dnaja1-/- mice revealed a primary defect 
of Sertoli cells in maintaining spermiogenesis at steps 8 and 9”6.  They also noted accumulation 
of the androgen receptor and increased transcription of androgen-responsive genes, such as Pem 
and Testin in Sertoli cells of Dnaja1-/- mice.  There was also evidence of disrupted Sertoli – germ 
cell adherens junctions in Dnaja1-/- mice6.  Figure 4 shows the expression profile of Dnaja1 in 
various tissues based on northern blot analysis.  It also shows histology of the testes in Dnaja1 
hetero and homozygous knockout mice.  Based on this histology, it is evident that homozygous 
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knockout males are producing some early germ cells, but fail to produce fully mature, elongated 
sperm.   Dnaja1-/- mice also had no structural defects, and were completely healthy6. For these 
reasons Dnaja1 was chosen for experimentation.  It would serve as an excellent model of 
isolated idiopathic infertility in men, and gene therapy at day 15 may have a potential positive 




High expression of type I DnaJs in testis and increased expression of DjA2 in DjA1−/− mice. (A, B) Sections of 
DjA1+/− and DjA1−/− testes were mounted on the same slide glass, and decorated with a mAb against DjA1. 
Peroxidase activity was visualized using 3,3′‐diaminobenzidine as a chromogen. Sections were counterstained with 
hematoxylin. Signals of DjA1 in primary and secondary spermatocytes are indicated with P and S, respectively (A). 
Nonspecific signals in the interstitial area are indicated with asterisks (A, B). (C, D) In situ hybridization of DjA1 
mRNA from DjA1+/− and DjA1−/− testes was carried out using digoxigenin‐labeled DjA1 probe. Alkaline 
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phosphatase activity was visualized using 5‐bromo‐4‐chloro‐3‐indolyl phosphate‐nitro blue tetrazolium as a 
chromogen. Sections were counterstained with nuclear fast red. (E) Total RNA samples from fractionated testicular 
cells and mouse tissues (5 μg each) were subjected to Northern blot analysis, using digoxigenin‐labeled DjA1 and 
DjA2 cRNAs as probes. Arrowheads indicate positions of 2.4 and 1.6 kb bands (DjA1) and 2.1, 2.2, 3.1 and 4.0 kb 
bands (DjA2). Protein samples of testicular cells (F) or tissues (G) were subjected to Western blot analysis using a 
monoclonal anti‐DjA1, or polyclonal anti‐DjA2 or anti‐DjB1 antibodies (0.4 μg/ml each), or antiserum against DjA4 
(1/1000 dilution). An arrowhead indicates position of expected size of DjA4.   
* Reused with permission from The EMBO Journal6
Figure 4. High expression of type 1 DnaJ in testis 
3.2 SPECIFIC AIM 2 
3.2.1 Dnaja1 Expression Profile 
As expected, Dnaja1 showed ubiquitous expression in mice.  Based on the results of the RT-
PCR, Dnaja1 was amplified in all mouse tissues, with apparent reduced expression in the uterus.  
This reduced expression in the uterus may be a results of the methods used to generate cDNA, so 
it is possible that it does not accurately represent the expression of Dnaja1 in mice.  The results 
of the RT-PCR for Dnaja1 on the mouse cDNA tissue panel are shown in Figure 5.  These 
results were compared to the BioGPS expression profile of Dnaja1 (available at 
http://biogps.org/#goto=genereport&id=ENSMUSG00000028410), which are shown in Figure 6.  
The BioGPS profile also shows ubiquitous expression.  The RT-PCR profile were concordant 
with the BioGPS data for Dnaja1, as well as the expressed sequence tag data presented compiled 
by NCBI.   
40 
Figure 5. Dnaja1 RT-PCR expression profile  
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Figure 6.  BioGPS expression profile for Dnaja1 in mice 
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3.2.2 Immunohistochemistry 
The cross section of the seminiferous tubules stained with DAB shows Dnaja1 expression in all 
cells in the seminiferous tubules.  It is likely that the antibody concentration and DAB exposure 
was too high, making it difficult to determine if this is an accurate representation of Dnaja1 
expression, or if the pattern is due to the oversaturated antibody and DAB exposure.  This IHC 
will need to be repeated for more accurate imaging.  Figure 7 shows the image obtained via 
Dnaja1 antibody staining in the testis.   
Figure 7. Dnaja1 antibody staining of seminiferous tubules 
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3.2.3 Dnaja1 sequence conservation analysis 
Genomic sequence alignment of human and mouse Dnaja1 shows 60% identity.  The amino acid 
sequence showed 99.5% sequence identity.  The primary functional domain of the DnaJ family is 
the J domain.  Within the J domain is a conserved sequence motif (JPS) that accelerates ATPase 
activity of Hsp70.  The ADP-bound state of Hsp70 binds polypeptide substrate.  This ATPase 
cycle is essential to the function of Hsp70 (Dnaja1) as a chaperone6.  Two other functional, 
conserved domains in the DnaJ family include a C-terminal substrate binding domain of DnaJ 
and Hsp40 that prevent aggregation of unfolded substrate, and a zinc finger domain as shown by 
the University of California Santa Cruz’s genome browser (shown in Figure 11 of discussion).  
3.3 SPECIFIC AIM 3 
3.3.1 Dnaja1 mouse breeding 
The results of several months of mouse breeding are summarized in Table 3.  No Dnaja1-/- pups 
were produced.  9 litters of pups have been born, ranging in size from 3 to 11, with an average 
size of about 6 mice.  The number of homozygous knockout mice is significantly lower than the 
expected mendelian ratio, and indicates that this mutation may be causing embryonic lethality in 
these mice.   
There is no abnormal phenotype seen in heterozygous mice, other than a possible 
unclassified pathogenesis in the male genitalia.  This only occurred in two of the males, and it is 
likely to be injury sustained from aggressive female mice.  Pictures of these two males are shown 
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in Figure 8.  Dnaja1 heterozygous mothers also ate several offspring, which is not unusual as 
these are new mothers.   
Male to female ratio 1:1 (23 males:24 females) 
Chi-square test p-value: 9.1 x 10-5 
Table 3. Dnaja1 mouse breeding results 
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3.3.2 Confirmation of Dnaja1 cDNA insertion 
Figure 9 shows the PCR used to confirm the insertion of the Dnaja1 cDNA into the lentiviral 
vector.  Each band represents one of eight bacterial colonies, five of which show three bands 
with the expected digestion pattern after EF1a-EGFP-T2A-Dnaja1 had been inserted into the 
lentiviral vector.  The top band represents circular DNA, the middle band represents linearized 
DNA with Dnaja1 insert, and the lower band shows linearized DNA without the Dnaja1 insert 
(empty vector).  The PCR was performed following an EcoRI restriction enzyme digest.  The 
vector insertion and confirmation was performed by Dr. Yi Sheng, MD, PhD.  
Figure 8.  Possible pathogenesis of male Dnaja1 heterozygotes 
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3.3.3 Confirmation of GFP and vector expression in testes 
Lentiviral vector expression was confirmed via GFP expression observed under epifluorescent 
microscopy.  At 10X and 20X magnification, GFP expression is clearly seen in the seminiferous 
tubules.  Figure 10 shows the GFP Tag expression studies.  Expression studies were performed 
by Yi Sheng, MD, PhD.  
Figure 9.  EcoRI restriction and PCR confirmation for Dnaja1 
cDNA insertion 
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Figure 10. GFP Tag expression 
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4.0  DISCUSSION 
4.1 DNAJA1 KNOCKOUT BREEDING 
Although it was expected that Dnaja1 homozygous knockout mice would be viable, with male 
infertility as the only damaging phenotype, these mice were unable to be produced through 
breeding of heterozygotes.  We suspect that this particular mutation of Dnaja1 is causing 
embryonic lethality.  Based on the assumption that one of every four mouse pups would have the 
homozygous knockout genotype, with 52 total pups approximately 13 homozygous knockout 
pups should have been produced.  It is highly unlikely that having zero of fifty – two pups being 
double knockouts is due to random chance.  A Chi – square test to examine this hypothesis gives 
a p-value of 9.1 x 10-5.    
To ensure that the genotyping results were not due to protocol errors, I used the UCSC 
genome browser to determine whether the wildtype primers might produce a PCR product seen 
on gel electrophoresis even in the absence of the wildtype allele.  According to the browser there 
is only one possible PCR product using this primer pair.  Therefore it is not suspected that the 
lack of homozygous recessive mice is a product of genotyping error.    
I performed further analysis of the Dnaja1 mutations produced by Terada et al. and the 
mutation produced by Jackson Laboratories and found that the embryonic lethality may be due to 
the size of the deletion in the Jackson Laboratories mutation.  Terada and colleagues deleted only 
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the J functional domain of Dnaja1, which included exons 2 and 3.  The mutation that Jackson 
Laboratories produced included exons 1-5.  As shown in Figure 11, this region includes two 
additional conserved domains of the DNAJA1 protein.  Domains not included in the Terada et al. 
knockout that are included in the Jackson Labs knockout include the C-terminal substrate 
binding domain of the DnaJ family as well as a Zinc finger domain.  The C-terminal region 
mediates oligomerization and binding to denatured polypeptide substrate, prevents the 
aggregation of unfolded substrate, and forms a ternary complex with both substrate and 
DNAJA1.  The Zinc finger domains of the DnaJ family are highly conserved and perform 
essential roles in protein translation, folding, unfolding, and degradation.  Their primary function 
is stimulating the ATPase activity of heat shock proteins.   The differences in the mutation offers 
a plausible explanation as to why the phenotype in the Jackson Mouse line would be more 








Dnaja1 contains 9 exons and is located between positions chr4:40,722,468 
and chr4:40,737,153.  The deletions constructed by Terada et al. only included exons 2 and 3, 
which encode the J domain of the protein product.  Jax deleted exons 1-5.  This regions 
encodes the J domain, a Zinc finger domain, and a c-terminal substrate binding domain.   
4.2 LENTIVIRAL VECTOR 
Because no Dnaja1-/- mice have been produced, the efficacy of the lentiviral vector was unable 
to be tested.  However, during the time that these mice were being bred, results did show that the 
Dnaja1 cDNA insert was successfully transfected into the viral vector, and that the vector is 
expressed in the seminiferous tubules.  Thus, preparations are in place to perform this experiment 
on future candidate genes.  We are continuing this project, and are now ready to test the lentiviral 
vector therapy on alternative candidate genes.    
Figure 11. DNAJA1 deletion 
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4.3 STUDY LIMITATIONS 
There are limitations to this study that may be assessed as the project continues.  First, 
expression studies of the viral vector were performed only in the testes.  It cannot be confirmed 
whether insertion of the vector will occur in other systems.  Although the vector will be injected 
directly into the testes, it may be possible for the virus to travel to other tissue, which may have 
unpredictable side effects on the mice, especially with the consideration that a universal 
promotor is being used.  Also, despite the viral vector expression studies using the GFP tag 
confirming expression of the vector in the seminiferous tubules, no cross – sectional view of the 
seminiferous tubules was taken.  Therefore it is not certain exactly which cells in the 
seminiferous tubules had been infected by the virus, and germ cell expression cannot be ruled 
out.  However, in prior experiments, Dr. Orwig’s group had not observed lentiviral vector 
expression in the germline.    
There are also limitations regarding clinical applications of lentiviral gene therapy.  
Although, as mentioned in the introduction, there are a number of clinical trials using lentiviral 
gene therapy that are either ongoing or approved, the therapy has not been approved for use in 
humans.  This type of therapy has been shown to be effective in several studies, but safety 
concerns for human use remain despite years of effort and improvement.  Lastly, at this time 
targets for lentiviral gene therapy to improve spermatogenesis in men are limited because there 
are very few known single-gene causes of infertility in human males.  As more research is done, 
however, this number is predicted to increase significantly.   
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4.4 FUTURE CONSIDERATIONS 
4.4.1 Alternative Candidate Genes 
There are several other candidate genes identified through this research that may be used as 
alternatives to Dnaja1.  For the next stage of the project, four genes will be used in the place of 
Dnaja1.  These genes are Cib1, Ar, Etv5, and Dhh.  Cib1 is a gene that was identified with a 
likely pathogenic variant on whole exome analysis in a male with unexplained infertility in our 
study population.  Mutations in this gene are known to cause isolated male infertility in mice, 
with the primary cause of azoospermia due to aberrant differentiation of Sertoli cells.  Targeted 
mutations of the Androgen receptor gene (Ar), which encodes the receptor for the hormone that 
regulates development and maintenance of the male sexual phenotype, have been shown to cause 
isolated azoospermia in male mice52.  Male mice with targeted disruption of Etv5 display Sertoli 
– cell only syndrome beginning at age 8 weeks due to aberrant spermatogonial stem cell 
regeneration.  This gene is expressed exclusively in Sertoli cells49; 51. Desert hedgehog (Dhh) 
male knockout mice produce no mature sperm, but are otherwise viable. This gene, expressed in 
Sertoli cells, regulates both early and late stages of spermatogenesis43. 
Other plans for lentiviral gene therapy include genes discovered through our primary 
research on men with idiopathic azoospermia or oligozoospermia.  These genes may be knocked 
out or mutated using clustered regularly interspaced short palindromic repeats, or CRISPRs.  The 
CRISPR system enables the creation of mouse models and reduces the time required to weeks, 
rather than months, to develop mutated mouse lines.  Methods of gene discovery are discussed 
below.   
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4.4.2 Future Candidate Gene Discovery 
Our research group will also continue its work to discover novel single-gene causes of male 
infertility, particularly azoospermia and oligozoospermia.  Methods of gene discovery include 
RNA expression, whole exome, and array comparative genomic hybridization studies at the 
genomic level.  Subjects for these studies are recruited primarily through the Reproductive 
Endocrinology and Infertility Clinic, as well as the Urology clinic of Magee-Womens   hospital.  
Men interested in the study have also been recruited through social media, online support groups, 




This section focuses on what I would have done differently from the outset of this project given a 
similar allotment of time, and knowing now what I have learned from this research.  Although 
several candidate genes that may be used for future experimentation were identified, in order to 
complete the project more efficiently I would have begun the search for candidate genes 
differently.  Performing raw searches of MGI, and finding a complete list of genes expressed in 
Sertoli cells may be useful in the long run, but since we had limited capacity to create mouse 
knockout lines, and limited time to complete the project it may have been wise to begin the 
search for candidate genes starting at the end of the filtration pathway rather than the beginning.  
What could have been done was to search mouse repositories, such as the Jackson Laboratories, 
for available knockout mouse lines first and then review the literature to determine whether these 
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genes would be appropriate for experimentation.  By searching mouse repositories first, the time 
spent finding genes appropriate for our purposes would have been significantly shorter.   
Another approach that could have been more productive and resourceful would be to seek 
assistance from researchers with experience in male infertility and Sertoli cell research.  As 
novices with regard to Sertoli cell genetics, beginning with the guidance of such an expert may 
have allowed us a more streamlined search for candidate genes.  Someone with this expertise 
could have also guided us with regard to details of these genes that may not be readily apparent 
through literature review.  Such individuals may have been found by searching for investigators 
within the Mage-Womens Research Institute with publications in Sertoli cell research, or that 
were currently investigating this subject.  We could have also found investigators throughout the 
country, or even internationally, by reaching out to those that had recently published in this area 
of research.  The search method I used was appropriate for identifying numerous candidate genes 
that can be used for a long term project, but this alternative process would have allowed for a 
more focused search and for a more efficient use of my time.    
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5.0  CONCLUSION 
This project offers insight for future development of lentiviral vector gene therapy to treat 
isolated male infertility.  Although few single-gene causes of male infertility have been identified 
in humans, hundreds of these genes are known to cause isolated infertility in mice, which may 
represent undiscovered causes of unexplained infertility in men.  If these single-gene defects can 
be corrected to restore spermatogenesis in mice with lentiviral gene therapy it is entirely possible 
that this therapy could be translated into the clinical setting.  This research has compiled several 
candidate genes to test the efficacy of lentiviral vector gene therapy for male infertility in mice, 
has shown that the viral vector is expressed in the target cells of the seminiferous tubules, and 
prepared an avenue for attempting this therapy on genes discovered in human males with 
unexplained azoospermia or oligozoospermia.  With continued efforts, the project serves as a 
foundation to prove that spermatogenesis can be restored in men with unexplained infertility, and 
that lentiviral gene therapy may serve as a viable option for treating infertility.   
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